CDK4 and nonpapillary renal cell carcinoma: Studies using the CDK4/6 inhibitor Palbociclib and the HIF-2α inhibitor PT2399 have demonstrated synergy in suppressing the viability of HIF-2α–dependent ccRCC cell lines [50].